Agentix Corp
OTC:AGTX
Agentix Corp
Agentix Corp.is a biotechnology company. The company is headquartered in Dana Point, California. The company went IPO on 2015-08-05. The firm is focused on the development of synthetic agonists, inverse agonists, and antagonists, which modulate the endocannabinoid system (ECS). The ECS is a network of G-protein-coupled receptors (GPCRs) that help regulate a variety of metabolic and neurotransmission functions. The company has licensed patented, synthetically derived, small molecule therapeutic candidates targeting the endocannabinoid GPCRs (CB1/CB2) for the treatment of metabolic syndrome and peripheral inflammation. The firm is also engaged in clinical trials of its product line. Its wholly owned subsidiary is GSL Healthcare, Inc.
Agentix Corp.is a biotechnology company. The company is headquartered in Dana Point, California. The company went IPO on 2015-08-05. The firm is focused on the development of synthetic agonists, inverse agonists, and antagonists, which modulate the endocannabinoid system (ECS). The ECS is a network of G-protein-coupled receptors (GPCRs) that help regulate a variety of metabolic and neurotransmission functions. The company has licensed patented, synthetically derived, small molecule therapeutic candidates targeting the endocannabinoid GPCRs (CB1/CB2) for the treatment of metabolic syndrome and peripheral inflammation. The firm is also engaged in clinical trials of its product line. Its wholly owned subsidiary is GSL Healthcare, Inc.
